Poziotinib (HM781-36B)

Base Information

• Chemical Name: Poziotinib (HM781-36B)
• CAS No.: 1092364-38-9
• Molecular Formula: C23H21Cl2FN4O3
• Molecular Weight: 491.349
• Mol file: 1092364-38-9.mol

Synonyms:Poziotinib;UNII-OEI6OOU6IK;1-(4-((4-((3,4-dichloro-2-fluorophenyl)aMino)-7- Methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one;1-[4-[[4-[(3,4-Dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one;poziotinib(HM-78136B);NOV120101;1-[4-[[4-[(3,4-Dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one Poziotinib;HM781-36B)

Chemical Property of Poziotinib (HM781-36B)

Chemical Property:

• Boiling Point: 629.7±55.0 °C(Predicted)
• PKA: 5.35±0.30(Predicted)
• PSA: 76.58000
• Density: 1.409±0.06 g/cm3(Predicted)
• LogP: 5.39460
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility.: Chloroform (Slightly), DMSO (Slightly, Sonicated)

Purity/Quality:

98%min ^*data from raw suppliers

Poziotinib >98% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Description: Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2. Poziotinib [1. {4. [4. (3,4. Dichloro.2.monofluoroaniline) -7-methoxyquinazoline-6. Oxygen]. 1. Piperidinyl} propan-2-ene-1one (1)] is a novel oral cancer cell inhibitor developed by Seoul Medical University in South Korea in 2008. It is used for the treatment of breast and gastric cancer, and has targeted Small molecule inhibitor of tyrosine kinase. It is currently in Phase II / III clinical research and can be used alone or in combination for the treatment of gastric, non-small cell lung cancer and breast cancer. Poziotinib is resistant to erlotinib and gefitinib EGFR L858R / T790M Double mutant cells have a strong inhibitory effect. The combined use of Poziotinib (HM781-36B) and 5-fluorouracil, platinum compound, paclitaxel or gemcitabine shows a good synergistic inhibitory effect on the overexpression of human epidermis No. 2 (HER2). A new third-generation anti-tumor cell inhibitor following the kinase inhibitor afatinib. Poziotinib is a TKI that covalently and irreversibly inhibits EGFR and HER2, and is unique because of its small terminal group and flexible quinazoline core. Its small size and flexibility allow it to evade the steric hindrance which affects other EGFR TKIs [138].
• Uses: Poziotinib can be used to inhibit the growth of cancer cells.

Technology Process of Poziotinib (HM781-36B)

There total 13 articles about Poziotinib (HM781-36B) which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 77.0%

4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol (1429757-65-2) + 1-acryloylpiperidin-4-yl 4-methylbenzenesulfonate (1620740-65-9) → 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one (1092364-38-9)

Guidance literature:

With potassium carbonate; In N,N-dimethyl acetamide; at 70 ℃; for 24h;

Reference yield: 77.0%

4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol (1429757-65-2) + 1-(3-chloropropanoyl)piperidin-4-yl 4-methylbenzenesulfonate (1620740-66-0) → 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one (1092364-38-9)

Guidance literature:

With potassium carbonate; In N,N-dimethyl acetamide; at 70 ℃; for 24h;

Reference yield: 57.0%

N-(3,4-dichloro-2-fluorophenyl)-7-methoxy-6-(piperidin-4-yloxy)quinazolin-4-amine dihydrochloride + acryloyl chloride (814-68-6,25189-84-8) → 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one (1092364-38-9)

Guidance literature:

With sodium hydrogencarbonate; In tetrahydrofuran; water; at 0 ℃; for 1h; Cooling with ice;

upstream raw materials:

4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol

1-acryloylpiperidin-4-yl 4-methylbenzenesulfonate

1-(3-chloropropanoyl)piperidin-4-yl 4-methylbenzenesulfonate

6-acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one

Downstream raw materials:

1-[4-[4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy]-piperidin-1-yl]prop-2-en-1-one hydrochloride

Refernces

• 1、 -. "HETEROCYCLIC INHIBITORS OF TYROSINE KINASE". Paragraph 0490-0492; 0529. . Retrieved 2020/11/03.
• 2、 -. "METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)PROP-2-EN-1-ONE". Page/Page column 10-11. . Retrieved 2014/08/07.